Stockscreener 앱 받기
444.64
7.83%
32.29
시간 외 거래:
450.50
5.86
+1.32%
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
Madrigal Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
MDGL’s Strategic Moves: Can They Leap Higher? - timothysykes.com
Madrigal Pharma Bets On Rezdiffra For Future Growth - Finimize
Madrigal Pharmaceuticals stock hits all-time high at 463.92 USD - Investing.com
Earnings call transcript: Madrigal Pharma Q3 2025 falls short of EPS forecast - Investing.com
[10-Q] MADRIGAL PHARMACEUTICALS, INC. Quarterly Earnings Report | MDGL SEC FilingForm 10-Q - Stock Titan
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth storyAnalyst Upgrade & Free Expert Verified Stock Movement Alerts - newser.com
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded by Bank of America to Neutral Rating - MarketBeat
Madrigal Pharmaceuticals Q3 Net Loss Widens, Revenue Rises - MarketScreener
Madrigal Pharmaceuticals Q3 2025 Earnings: EPS Misses, Revenue S - GuruFocus
Madrigal Pharmaceuticals (MDGL) Reports Strong Q3 Revenue Boost - GuruFocus
Madrigal: Q3 Earnings Snapshot - San Antonio Express-News
Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q3 Revenue $287.3M, vs. FactSet Est of $247.3M - MarketScreener
Madrigal Pharma Q3 revenue rises on Rezdiffra demand - MarketScreener
B of A Securities Upgrades Madrigal Pharmaceuticals (MDGL) - MSN
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
[8-K] MADRIGAL PHARMACEUTICALS, INC. Reports Material Event | MDGL SEC FilingForm 8-K - Stock Titan
Madrigal Pharmaceuticals (NASDAQ: MDGL) reports $287.3M Q3 sales, up from $62.2M - Stock Titan
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsWeekly Gains Summary & Growth Oriented Trading Recommendations - newser.com
Can Madrigal Pharmaceuticals Inc. stock beat market expectations this quarterWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Madrigal Pharmaceuticals Q3 2025 Earnings Preview - MSN
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikes2025 Market WrapUp & Daily Price Action Insights - newser.com
Visual analytics tools that track Madrigal Pharmaceuticals Inc. performanceJuly 2025 Setups & Daily Stock Trend Watchlist - newser.com
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.Long Setup & Accurate Technical Buy Alerts - newser.com
Will Madrigal Pharmaceuticals Inc. stock gain from lower inflationMarket Risk Report & Smart Investment Allocation Tips - newser.com
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.Portfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stock2025 Market Sentiment & Community Consensus Trade Alerts - newser.com
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.July 2025 Snapshot & Daily Profit Maximizing Tips - newser.com
Madrigal Pharmaceuticals (MDGL) Upgraded to Neutral by BofA on R - GuruFocus
Madrigal Pharmaceuticals upgraded at BofA on Rezdiffra uptake - Seeking Alpha
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potential2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
MDGL: B of A Securities Upgrades Madrigal Pharmaceuticals to Neu - GuruFocus
MDGL: B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals stock rating upgraded by BofA on strong launch - Investing.com Canada
BofA Upgrades Madrigal Pharmaceuticals to Neutral From Underperform, Price Target is $445 - MarketScreener
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthEarnings Risk Summary & Free High Return Stock Watch Alerts - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownWeekly Risk Summary & Weekly Market Pulse Alerts - newser.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Can Madrigal Pharmaceuticals Inc. stock hit record highs againJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthJuly 2025 Institutional & Weekly High Potential Stock Alerts - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis tools2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Madrigal Pharmaceuticals Inc. stock chart pattern explained2025 Technical Patterns & Risk Managed Investment Signals - newser.com
1.45%
0.86%
자본화:
|
볼륨(24시간):